An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia

Jun Ma; Ting Liu; Jie Jin; Jianda Hu; Qifa Liu; Jianxiang Wang; Zhixiang Shen; Xin Du; Bin Jiang; Xianhua Meng

doi:10.2217/ijh-2018-0006

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia

Int J Hematol Oncol. 2018 Jul 25;7(2):IJH06. doi: 10.2217/ijh-2018-0006. eCollection 2018 Jun.

Authors

Jun Ma^{1

1}, Ting Liu^{2

2}, Jie Jin^{3

3}, Jianda Hu^{4

4}, Qifa Liu^{5

5}, Jianxiang Wang^{6

6}, Zhixiang Shen^{7

7}, Xin Du^{8

8}, Bin Jiang^{9

9}, Xianhua Meng^{10

11

10

11}

Affiliations

¹ Department of Hematology, Harbin Institute of Hematology & Oncology, Harbin, China.
² Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
³ Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
⁴ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
⁵ Department of Hematology, Southern Medical University Nanfang Hospital, Guangzhou, China.
⁶ Department of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.
⁷ Department of Hematology, Shanghai Ruijin Hospital, Shanghai, China.
⁸ Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, China.
⁹ Department of Hematology, Peking University People's Hospital, Beijing, China.
¹⁰ Department of Biostatistical Science, Amgen R&D Asia, Shanghai, China.
¹¹ Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.

Abstract

Aim: Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.

Patients & methods: We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.

Results: Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).

Conclusion: This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.

Keywords: ALL; China; Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia; acute lymphoblastic leukemia; chemotherapy; relapsed/refractory; retrospective observational study.